Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748747 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT01748747: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01748747 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01748747, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cell tumor cells. Biological therapies, such as resiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether Gag:267-274 peptide vaccine and resiquimod are more effective when given together or separately
Interventions
- OTHER laboratory biomarker analysis
- DRUG Montanide ISA 51 VG
- BIOLOGICAL MART-1 antigen
- DRUG resiquimod
- BIOLOGICAL Gag:267-274 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-03-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748747
The ClinicalTrials.gov registry entry for NCT01748747 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01748747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01748747 about?
NCT01748747 is a clinical study titled "Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery". This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cell tumor cells. Biological therapies, such as resiquimod,...
What is the current status of trial NCT01748747?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2012-10. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT01748747?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Montanide ISA 51 VG (DRUG), MART-1 antigen (BIOLOGICAL), resiquimod (DRUG), Gag:267-274 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01748747?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.